Wednesday, December 5, 2018 @ 1:30 pm
BioVersys is strengthening its executive management team with the appointment of Dr. Glenn E. Dale as Chief Development Officer as of February 1st, 2019. He will lead clinical development activities and brings 25 years of R&D experience and significant knowledge in the modern development of antibiotics, having already successful guided several compounds through preclinical development and into Phase III clinical trials.
Combating resistant bacterial infections is an ever-increasing global health problem towards which BioVersys is developing a pipeline of differentiated experimental drugs. Our most advanced compounds for nosocomial infections and Tuberculosis will enter first Phase I clinical trials within the next 12 months.
Glenn joins BioVersys from Polyphor AG where he led the Antibiotic Research and Early Development, successfully transitioning the antibiotic Murepavadin from early clinical phases to Phase III studies. He played a key role in the discussions with regulatory authorities and in agreeing a pathogen specific clinical development plan which allowed the initiation of Phase III clinical trials that can lead to approval in both the USA and Europe.
Glenn’s primary mission will be to guide the transition of BioVersys into a clinical stage development company with the initiation of our first Phase I clinical trials anticipated in 2H 2019.
Dr. Marc Gitzinger, CEO and co-founder of BioVersys: “We are extremely delighted that Glenn has chosen to join BioVersys during an exciting and important stage in our company’s development. We are now moving our candidate molecules through late stage preclinical development and preparing to initiate our first Phase I clinical trials in the 2H 2019. Glenn’s significant antibiotic drug development experience will be a major asset to the company”.
Glenn comments: “I am excited to join BioVersys, with its evolving pipeline of traditional and non-traditional antibiotics. The company represents a new generation of innovative antimicrobial resistance biotechs. I’m looking forward to the challenge of moving novel compounds into clinical development for BioVersys, and to continue to contribute in the AMR field, where we have a lack of truly novel treatment options and many patients are still not getting the life-saving therapy they need.”
Dr. Seng Chin Mah, Chairman of BioVersys: “We are delighted with BioVersys’ evolution from a research-driven spin-off towards a clinical stage development company. A measure of the success of a biotech is the ability to retain and attract bright and experienced people. The addition of Glenn represents a commitment of BioVersys to investing in human capital critical to the future success of the company. We look forward to advancing our strong pipeline and bringing these innovative therapies to patients as quickly as possible.”